FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease

Approval aligns with Centers for Disease Control and Prevention’s recommendations for meningococcal vaccination September 11, 2014 Sanofi Pasteur, the vaccines division of Sanofi , announced today that the U.S. Food and Drug Administration (FDA) approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years …

Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine

June 17, 2014 Pfizer Inc. announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Each year, approximately 500,000 cases of meningococcal disease occur worldwide …

New Report from the National Foundation for Infectious Diseases Reviews Recent Meningococcal Disease Outbreaks on College Campuses

Report Identifies Challenges and Includes Recommendations for Management of Future Meningococcal Disease Outbreaks May 22, 2014 An expert panel assembled by the National Foundation for Infectious Diseases (NFID) examined recent meningococcal disease outbreaks on multiple college campuses in the United States and concluded that despite its rarity, the severe nature of meningococcal disease makes advance planning essential. These outbreaks were particularly challenging …

Pfizer’s Bivalent rLP2086 Receives FDA Breakthrough Therapy Designation for Potential Prevention of Meningococcal B

Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease Pfizer Intends to Submit Biologics License Application for Bivalent rLP2086 to U.S. Food and Drug Administration by Mid-2014 March 20, 2014 Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation …